For example, the mutant P53 protein has been considered a new target for immunotherapy in melanoma, and the new biological drug ALT-801, which specifically targets P53 protein, is currently in a phase II clinical trial in combination with cisplatin in metastatic melanoma (Chasov et al., 2021). Here, TP53 is linked to metastatic melanoma.